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Abstract
Background: To evaluate the intermediate-term health outcomes associated with a soy-based
meal replacement, and to compare the weight loss efficacy of two distinct patterns of caloric
restriction.
Methods: Ninety overweight/obese (28 < BMI ≤ 41 kg/m2) adults received a single session of
dietary counseling and were randomized to either 12 weeks at 1200 kcal/day, 16 weeks at 1500
kcal/d and 12 weeks at 1800 kcal/d (i.e., the 12/15/18 diet group), or 28 weeks at 1500 kcal/d and
12 weeks at 1800 kcal/d (i.e., the 15/18 diet group). Weight, body fat, waist circumference, blood
pressure and serum lipid concentrations were measured at 4-week intervals throughout the 40-
week trial.
Results: Subjects in both treatments showed statistically significant improvements in outcomes. A
regression model for weight change suggests that subjects with larger baseline weights tended to
lose more weight and subjects in the 12/15/18 group tended to experience, on average, an
additional 0.9 kg of weight loss compared with subjects in the 15/18 group.
Conclusion: Both treatments using the soy-based meal replacement program were associated
with significant and comparable weight loss and improvements on selected health variables.
Background
Obesity is a medically serious [1] and increasingly preva-
lent condition in the United States [2] associated with
increased morbidity [3], mortality rate [4], impaired
health related quality of life [5] and reduced life expect-
ancy [6]. Although it is uncertain whether intentional
Published: 18 November 2003
Nutrition Journal 2003, 2:14
Received: 25 September 2003
Accepted: 18 November 2003
This article is available from: http://www.nutritionj.com/content/2/1/14
© 2003 Fontaine et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/14
Page 2 of 7
(page number not for citation purposes)
weight loss increases longevity [7], it is well documented
that losing weight improves health [8] and quality of life
[9]. Thus, promoting sustained weight loss remains an
important treatment goal for obese individuals. We [10]
recently demonstrated that a program involving a soy-
based meal replacement formula is effective in lowering
weight, fat mass and in reducing LDL cholesterol. Because
this study was only a 12-week trial, we could not evaluate
the intermediate-term effects of the treatment. The pri-
mary purpose of this study reported herein was to conduct
a trial to evaluate the intermediate-term changes among
subjects on weight and several weight-related variables
such as blood pressure and serum lipid concentrations. A
second purpose of the study was to compare the weight
loss efficacy of two distinct recommended patterns of
caloric restriction. Finally, because a proportion of our
participants were members of the control group in our
first study [10], we were able to evaluate whether their
prior participation as controls influenced their response
to the weight loss intervention.
Methods
Study Design
The study is a controlled randomized parallel group 40-
week trial to compare the intermediate-term weight-loss
efficacy of two patterns of prescribed calorie restriction
using a soy-based meal replacement product. Subjects
were randomly assigned to a sequence of either 12 weeks
at 1200 kcal/day, 16 weeks at 1500 kcal/d and 12 weeks at
1800 kcal/d (the 12/15/18 diet group), or 28 weeks at
1500 kcal/d and 12 weeks at 1800 kcal/d (the 15/18 diet
group). Secondary outcomes were body fat, waist circum-
ference, serum lipid concentrations and blood pressure.
Subjects
Overweight/obese persons with body mass index (BMI;
kg/m2) between 28 and 41 (men: n = 13 and women: n =
86) between the ages of 35 and 65 were enrolled in this
trial. Exclusion criteria were: weight loss >5 kg in the past
3 months, use of weight loss medication within the past 6
weeks, scores above the 90th percentile on the Brief Symp-
tom Inventory (BSI, a screening measure of general psy-
chological functioning), presence of disease not believed
to be at least partially the result of obesity and treatable by
weight reduction, medical or psychological contraindica-
tions as determined by study investigators, or known
hypersensitivity to any of the ingredients of the formula,
including but not limited to, soy protein. The study was
approved by the IRB at St. Luke's/Roosevelt Hospital, and
all subjects provided written informed consent. Prior to
participation and acceptance into the program, subjects
were deemed medically fit for safe weight loss through a
physical examination. After meeting eligibility criteria,
candidates were randomized via computer-generated
pseudo random numbers at a 1:1 allocation ratio, without
regard to race or sex, to one of two treatment groups
described below. Thirty-seven subjects enrolled in this
trial had formerly been the control group for a 12-week
weight loss study which has been described elsewhere
[10]. An additional 62 were newly recruited from clinic
records and advertisements in the local press.
Ninety-nine subjects were randomized, 50 into the 12/15/
18 treatment group and 49 into the 15/18 treatment
group. Sixty-one subjects remained after 12 weeks, 42
after 24 weeks, and 30 subjects completed the 40-week
trial.
Treatment Conditions
All subjects received the Scan Diet meal-replacement for-
mula, instructions for its use, a single session of dietary
counseling and a pamphlet describing healthy weight loss
practices. The 12/15/18 treatment group was instructed to
begin with a 1200 kcal daily diet that consisted of 5 Scan
Diet Shakes, 4 exchanges of fruit, 4 exchanges of vegeta-
bles and 1 fat exchange. They were given a copy of the
Nutricia Scan Diet Meal Plan booklet, describing the diet,
as well as a copy of The American Dietetic Association's
booklet "Exchange Lists for Weight Management." After
12 weeks the diet instruction was changed to 1500 kcal
daily consisting of 3 Scan Diet Shakes, 5 carbohydrate
exchanges, 7 exchanges of fruit and vegetables, 5 meat
exchanges and 2 fat exchanges. After 16 weeks the diet was
increased to an 1,800 kcal/d made up of 2 Scan Diet
Shakes, 2 milk, 9 carbohydrate, 8 fruit and vegetable, 8
meat and 3 fat exchanges. The 15/18 group began their
weight loss program at the 1500 kcal/day level and was
instructed to follow it for 28 weeks. After 28 weeks the diet
was increased to the 1800 kcal/d level, as described above,
for the final 12 weeks.
Measures
Throughout the study, subjects made visits to the clinic at
4 week intervals. At each visit, subjects were checked for
compliance and supplied with sufficient meal replace-
ment formula to last until the next scheduled visit, plus
one additional week. At each visit anthropometric meas-
ures, blood pressure, and psychological wellness assess-
ments were obtained. Blood samples for laboratory
assessment included standard blood work at initial
screening (i.e., complete blood count and serum lipids)
and lipids and serum at weeks 4, 8, 12, 16, 24, 32 and 40.
Samples were analyzed by a commercial lab (Quest Diag-
nostics, Teterboro, NJ). Body weight was measured within
0.1 kg using a standardized calibrated scale. Height was
measured within .10 cm using a wall-mounted stadiome-
ter. Body fat was measured through the use of a TANITA
bio-impedance analyzer (TBF 305) and waist circumfer-
ence was taken with a non-distensible tape measure
according to published guidelines [11,12]. Blood pressureNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/14
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was measured after at least 5 minutes rest using a standard
mercury sphygmomanometer and appropriately sized
cuffs according to the guidelines of the American Heart
Association. Side effects and adverse events were assessed
by a standardized interview/questionnaire, the Monitor-
ing of Side Effects Scale [13]. The 70-items are answered
on a 5-point scale ranging from 0 = not present to 4 =
severe.
Statistical Analysis
The principal aim of the analysis was to compare the
effects of the two diet prescriptions over time on the pri-
mary and secondary outcomes. We also investigated pos-
sible differences in treatment response by the subjects
who had been the control group in a previous study with
the response of newly recruited subjects.
In initial exploratory analyses, we used two-sample inde-
pendent t-tests to compare changes from baseline
between the two treatment groups at each follow-up visit
for, first, only newly recruited subjects and, second, for all
subjects. This analysis was used to determine if differences
between groups were more apparent for newly recruited
subjects. T-tests were also used to assess changes from
baseline at each follow-up visit. In this latter analysis, the
two treatment groups were combined but separate analy-
ses were run for subjects obtained from our short-term
trial [[10], referred to as Study 1], newly recruited subjects,
and all subjects together.
We also employed mixed effects regression models with
subject as a random effect. This technique accommodated
the evaluation of multiple terms in a single model, the
evaluation of potentially significant interaction terms,
and missing data due to drop-out [14]. These mixed
effects models were computed for changes in weight, body
fat, waist circumference, total cholesterol (TC), low den-
sity lipoprotein cholesterol (LDL), high density lipopro-
tein cholesterol (HDL), the proportion of TC as HDL (i.e.,
HDL/TC), triglycerides, and systolic and diastolic blood
pressure.
A typical model was of the form,
Yij = β0 + β1(Timeij) + β2(Timeij)2 + β3(Basei) + β4(GRPi) +
β5(IN1i) + Si + εij
where the j subscript denotes a follow-up visit, the i sub-
script denotes subject, and Yij, the dependent variable is
the change from baseline (e.g., follow-up weight – base-
line weight), Time is the number of weeks since the initial
baseline visit, Base is the baseline value of the outcome
variable, GRP= 1 for subjects in the 15/18 group and zero
for the 12/15/18 group, IN1 = 1 for subjects who partici-
pated in the initial study and 0 for newly recruited sub-
jects, S is a random effect term for each subject assumed
to have a zero mean and variance  , ε represents ran-
dom errors assumed to be normally distributed with
mean zero, variance σ2, and is assumed to be independent
of S. Time was coded as a numeric quantity which allowed
the development of a functional relationship between
Time and change from baseline. Once a model is selected
and fitted to the data for a particular outcome variable, the
interrelationships between GRP, Time, Base, and IN1 were
assessed.
Results
Baseline characteristics of subjects enrolled in the trial are
shown in Table 1. Thirty-six percent of subjects were Euro-
pean-American, 34% African-American, 20% Hispanic-
American, and 10% other or unknown. Adherence to die-
tary prescription was measured by counting meal replace-
ment packages consumed as a proportion of the number
of packages that should have been consumed had the sub-
ject used exactly the prescribed amount of soy product,
and was expressed as a percentage. Mean group adherence
did not differ statistically between the groups and ranged
between 48 and 70% in both groups, except for the final
month of the study when it was lower (43–48%). Regres-
sion analysis showed that in both groups amount of
weight loss during the trial was positively related to degree
of adherence (p = 0.0013).
The results for weight change are presented in detail
below. Following these, results for the remaining variables
are presented in summary. Details of all analyses and
results for all study variables, as well as figures, can be
obtained upon request.
Body Weight
Figure 1 shows the average change in weight from baseline
at each visit for all subjects who made the visit. For the
first 4–8 weeks the declines in weight appear to be similar
at both levels of caloric restriction but between weeks 12
and 20 the difference between the 1200 and 1500 calorie
allocation for the first 12 weeks seems to be reflected in a
greater weight loss for the more aggressively restricted
group. T-tests showed that the difference only reaches sta-
tistical significance among the newly recruited subjects at
the 8 week follow-up visit (P = 0.047). This greater weight
loss is retained until the end of the study in the subjects
from Study 1 but not in those newly recruited. Newly
recruited subjects in the 12/15/18 group achieved their
largest mean weight loss at the 16 week visit (6.44 kg)
while those in the 15/18 group had the largest mean
weight loss at the 28 week visit (6.57 kg).
The best fitting mixed effects model for weight change is,
σ S
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Table 1: Measured Baseline Subject Characteristics (Mean and SD = standard deviation)*
Characteristic 12/15/18 Group 15/18 Group
N Mean (SD) N Mean (SD)
Age, yrs 50 47.7 (8.3) 49 48.7 (8.8)
Weight, kg 50 91.0 (12.5) 49 93.5 (14.3)
Body mass index (BMI: kg/m2) 50 34.0 (3.5) 49 34.6 (3.6)
Total body fat mass % 49 44.4 (5.8) 49 44.4 (5.2)
Fat mass, Kg 49 40.3 (8.6) 49 41.9 (9.7)
Waist circumference 49 98.0 (9.3) 49 100.2 (9.4)
Total cholesterol, mg/dL 48 194.8 (33.0) 49 209.8 (38.7)
LDL cholesterol, mg/dL 48 121.5 (28.4) 48 134.0 (37.3)
HDL cholesterol, mg/dL 48 54.2 (12.6) 49 51.4 (11.6)
Diastolic blood pressure, mm Hg 49 80.1 (8.9) 49 78.2 (7.0)
Systolic blood pressure, mm Hg 49 121.9 (16.0) 49 118.9 (14.2)
Triglyceride, mg/dL 48 95.7 (57.5) 49 131.1 (83.9)
* Ns differ because some measures were missing and because the 15/18 group had 49 subjects owing to a clerical error.
Changes in weight for subjects from Study 1 and newly enrolled for the 12/15/18 and 15/18 groups* Figure 1
Changes in weight for subjects from Study 1 and newly enrolled for the 12/15/18 and 15/18 groups* *The left Y axis is the scale 
of weight change for subjects in study 2 only, while the right Y axis is the scale of weight change for subjects who were in study 
1. Last time point of 12/15/18 group with subjects were in study 1 is not showing because there were only 4 cases for the 
point, and the mean was -7.6 kg, SE was 4.1 kg.
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∆WT = 2.12 - 0.209Time + 0.005 (Time)2 - 0.058Base +
0.926GRP + 2.117IN1 + S
where ∆WT is the predicted weight change from the fitted
model and S is a random effect that is estimated for each
subject. The independent predictor variables, Time,
(Time)2, Base and IN1 were significant (α = 0.05), but GRP
was not (P = 0.171). No higher order interactions were
found to be significant. Time ranged from a minimum of
2.86 weeks (first follow-up visit) to a maximum of 49
weeks (the final follow-up visit).
We interpret the model as follows. Subjects tend to lose
weight over time (-0.209 Time) but the loss is less pro-
nounced at later visits. Subjects with larger baseline
weights tended to lose more weight. Newly recruited sub-
jects lost, on average, 2.1 kg more than subjects from
Study 1, not surprising since subjects who had been in
study 1 entered study 2 already 2.9 kg below their study 1
baseline weight having lost some weight as the control
group in the previous study [10].
Body Fat and Waist Circumference
The mixed effects models for total body fat change indi-
cated that, as for body weight, subjects tend to lose total
body fat over time but the loss is less pronounced at later
visits due to a positive quadratic effect of time. The rate of
change in body fat over time depended on whether sub-
jects had been in the previous study. There were no signif-
icant differences between the two treatments on loss of
either body fat or total body fat expressed as a percentage
at any single follow-up visit.
The best mixed effects model for waist circumference
change indicated that subjects' waist circumference
decreased over time but the decrease was less pronounced
at later visits. Subjects with larger initial waist circumfer-
ence showed larger decreases and subjects in the 12/15/18
group experienced, on average, an additional 1.729 cm of
waist circumference decrease versus subjects in the 15/18
group. Significant differences were observed between the
two treatments at week 4, 8, 12, and 16. In each case,
reductions were greater in the 12/15/18 group.
Serum lipid
The mixed effects model for cholesterol indicates that
there is an initial overall decrease in cholesterol of a mag-
nitude related to baseline value and that, over time, the
cholesterol tends to increase but at a decreasing rate. Sub-
jects in the 12/15/18 group tended to experience, on aver-
age, an additional 7.64 mg/dl reduction in total
cholesterol compared with subjects in the 15/18 group.
The models for HDL and LDL cholesterol change, as for
total cholesterol, showed an initial decrease of a magni-
tude related to baseline value followed by a regain over
time, but at a decreasing rate. For LDL, newly recruited
subjects decreased 6.764 mg/dl more than subjects from
Study 1. A significant interaction indicates that the rate of
LDL change over time depends on the baseline value.
The mixed effects model for HDL/ Total Cholesterol
change had only one significant term, the baseline value,
with a coefficient indicating that subjects with higher
baseline values showed larger decreases in HDL/TC. T-
tests on changes from baseline show that, at all time
points throughout the study, the HDL/TC improvement
from baseline was highly significant (p < 0.002).
Triglyceride changes were not significantly related to any
of the individual variables in the mixed effects model. Sig-
nificant interaction effects indicate that the relation of the
baseline value to the amount of triglyceride change
depended on the group and whether subjects had served
as controls in the prior study.
Blood Pressure
The mixed effects models for blood pressure change indi-
cate that subjects' blood pressure decreased over time but
the decrease is less pronounced at later visits. Subjects
with higher baseline values showed larger decreases.
Newly recruited subjects tended to decrease more than
subjects who had been in Study 1, and subjects in the 12/
15/18 group tended to experience a greater blood pressure
reduction than subjects in the 15/18 group. By t-test we
observed significant differences between the groups on
diastolic blood pressure at weeks 16 and 28 with the 12/
15/18 group producing the greater reduction.
Differences from baseline
On the whole, we observed significant differences on the
primary and secondary outcomes when we compared
changes at each follow-up clinic visit with baseline values.
This pattern is reflected in the significance of the time var-
iable coefficient in most mixed model analyses. Excep-
tions were observed on triglycerides and SBP, where the
pattern of findings was less consistent. The change from
baseline was particularly evident in newly recruited sub-
jects; however, in general, it was also apparent when the
analysis was carried out on only Study 1 subjects. The
smaller effect seen in subjects who had previously served
as controls may be a consequence of the fact that they had
already lost an average of 2.9 kg during the previous 3
months.
Discussion
This 40-week weight loss trial comparing two distinct pat-
terns of caloric restriction indicated that, on the whole,
both protocols were associated with fairly similar magni-
tudes of beneficial weight loss, as well as similar beneficialNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/14
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changes on health variables. When newly recruited sub-
jects and previous control subjects were pooled there were
no significant differences between the calorie restriction
groups on weight loss, body fat, total cholesterol, HDL
cholesterol and triglycerides at each assessment. Signifi-
cant differences were observed on WC, LDL cholesterol
and blood pressure at various assessment points, and, in
these cases, the magnitude of the change was greater for
the 12/15/18 group.
The exact implications of the observed cholesterol
changes are not immediately apparent because of the
simultaneous variation in the total and fractions of cho-
lesterol. Decreases seen in total and LDL levels, which
would be interpreted as beneficial, are accompanied by a
decrease in HDL, which is known to have a protective
effect. One resolution is to use a combination measure
such as the HDL/total cholesterol index which has been
shown to have stronger associations with coronary heart
disease than the individual cholesterol components [15].
In this study the HDL/total cholesterol index was signifi-
cantly improved over baseline in both groups at every
time point.
The results of the mixed models were generally consistent:
no matter the health variable in question, subjects tend to
have a desirable change in the outcome over time, with
the largest changes occurring earlier in the trial. Moreover,
subjects with less desirable baseline values (e.g., larger
waist circumference) tended to show a change of greater
magnitude. Finally, subjects in the 12/15/18 group
tended to experience, on some measures, additional
change on the outcome versus subjects in the 15/18
group.
There was also a tendency for newly recruited subjects to
show greater improvements than subjects who had previ-
ously served as controls. The IN1 variable was positive in
all models although it only occasionally reached conven-
tional significance levels. This may be the result of the
weight loss that had previously occurred in the control
group, making it more difficult for subjects to lose addi-
tional weight in this follow-up study. Study designs which
call for re-randomization of subjects who previously
served as controls should consider the possibility of
diminished effects.
This study has limitations. First, this 40-week trial did not
include a non treatment control condition. Thus, we were
unable to evaluate the effects of the two treatments com-
pared with the absence of treatment. In this regard, how-
ever, our previous study (10) demonstrated that, over 12-
weeks, assignment to the soy-based meal replacement
program caused reductions in weight and improvements
on health variables compared with receiving only dietary
advice. In addition, the outcome measures are substan-
tially improved during and at the end of the study period
compared to baseline values. Nonetheless, the absence of
a no treatment control group in this trial limits the conclu-
sions that can be drawn.
Second, because of the duration of the study and the min-
imal intervention offered, only 30% of the subjects com-
pleted the entire trial. Although high attrition rates are not
uncommon even in shorter-term weight loss trials [16], it
raises the possibility that our results may not be represent-
ative of all persons who take part in this, or a similar,
weight loss protocol.
Conclusions
This 40-week trial indicates that a reduced calorie deficit
diet that includes a soy-based meal replacement shake
produces significant changes on body weight and on
selected health variables. Adherence to the prescribed
degree of soy product usage remained relatively constant
throughout, except for the final month. Greater adherence
was associated with greater weight loss during the trial.
Finally, both patterns of caloric restriction were effective
in promoting weight loss and were associated with com-
parable levels of weight loss over the course of the trial. In
general, this was also the case with regard to important
health variables such as blood pressure and serum lipid
concentrations.
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